Syrian authorities have destroyed some 100 million Captagon pills discovered in a warehouse near the port of Latakia according to a report by the sta ...

Harmony Biosciences (HRMY) pre-announced 2024 preliminary net revenue from WAKIX, its lead product, which is FDA-approved in ...

Among the myriad drugmakers laying out their plans for the future at this year’s J.P. Morgan Healthcare Conference, Takeda ...

New genetic risk factors for depression have been identified across all major global populations for the first time, allowing scientists to predict risk of depression regardless of ethnicity.

The narcolepsy treatment market is projected to grow from USD 5,301.6 million in 2024 to USD 8,718.3 million by 2034, at a ...

Under the new bill, Illinois would increase the age for mandatory behind-the-wheel driving tests from 79 to 87. The proposal ...

At the start of each of the last five years, the share price of Alkermes has increased. It’s the kind of steady trajectory ...

The FDA has expanded the approval of Lumryz (sodium oxybate) extended-release oral suspension to include treatment of pediatric narcolepsy.

CNW/ - Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, today announced that its affiliate Nuvo Pharmaceuticals (Ireland) DAC has acquired the United States rights to ...

Avadel Pharmaceuticals missed the fourth quarter sales estimate by 5.12%. Still, the sales of its narcolepsy drug, LUMRYZ ...

Avadel Pharmaceuticals expects its narcolepsy treatment Lumryz to drive strong revenue growth in the fourth quarter and into 2025, preliminary earnings show.